Abstract
Stressors may instigate a series of hormonal variations, coupled with neurochemical alterations within the brain that promote cognitive alterations and favor the development of depressive illness. Indeed, it appears that in many respects the effects of stressors are reminiscent of the presumed neurochemical disturbances thought to be associated with depression, including elevated hypothalamic-pituitary-adrenal (HPA) functioning, as well as altered monoamine activity within hypothalamic and limbic areas of the brain. With respect to the latter, it has become clear that stressors reliably induce variations of brain norepinephrine (NE), dopamine (DA), and serotonin (5-HT) and that the behavioral disturbances associated with stressors are alleviated by treatments that attenuate the amine alterations, including antidepressant agents (1).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Anisman, H., Zalcman, S., Shanks, N., and Zacharko, R. M. (1991) Multisystem regulation of performance deficits induced by stressors: An animal model of depression, in Neuromethods: Animal Models of Psychiatry, II, vol. 19. (Boulton, A., Baker, G., Martin-Iverson, M., eds.), Humana Press, Totowa, NJ, pp. 1ā59.
Maes, M. (1999) Major depression and activation of the inflammatory response system. Adv. Exp. Med. Biol. 461, 25ā46.
Blalock, J. E. (1994) The syntax of immune-neuroendocrine communication. Immunol. Today 15, 504ā511.
Rothwell, N. J. and Hopkins, S. J. (1995) Cytokines and the nervous system. II:Actions and mechanisms of action. Trends Neurosci. 18, 130ā136.
Maes, M. (1995) Evidence for an immune response in major depression: a reviewand hypothesis. Prog. Neuropsychopharmacol. Biol. Psychiatry 19, 11ā38.
Licinio, J. and Wong, M. L. (1999) The role of inflammatory mediators in thebiology of major depression: central nervous system cytokines modulate thebiological substrate of depressive symptoms, regulate stress-responsive systems, and contribute to neurotoxicity and neuroprotection. Mol. Psychiatry 4,317ā327.
Yirimaya, R., Weidenfeld, J., Pollak, Y., Morag, M., Morag, A., Avitsur, R., et al. (1999) Cytokines, ādepression due to a general medical condition,ā andantidepressant drugs. Adv. Exp. Med. Biol. 461, 283ā316.
Anisman, H., Zalcman, S., and Zacharko, R. M. (1993) The impact of stressorson immune and central neurotransmitter activity: bidirectional communication.Rev. Neurosci. 4, 147ā180.
Dunn, A. J. (1995) Interactions between the nervous system and the immunesystem, in Psychopharmacology: The Fourth Generation of Progress (Bloom, F. E. and Kupfer, D. J., eds.), Raven, NY, pp. 719ā731.
Dantzer, R., Bluthe, R. M., Aubert, A., Goodall, G., Bret-Dibat, J.-L., Kent, S., et al. (1996) Cytokine actions on behavior, in Cytokines and the Nervous System.(Rothwell, N. J., ed.), Landes, London, pp. 117ā144.
Ek, M., Kurosawa, M., Lundenberg, T., and Ericsson, A. (1998) Activation of vagal afferents after intravenous injection of interleukin-1Ī²: role of endogenous prostaglandins. J. Neurosci. 18, 9471ā9479.
Maier, S. F. and Watkins, L. R. (1998) Cytokines for psychologists: implicationsof bidirectional immune-to-brain communication for understanding behavior,mood, and cognition. Psychol. Rev. 105, 83ā107.
Banks, W. A., Ortz, L., Plotkin, S. R., and Kasten, A. J. (1991) Humaninterleukin (IL) 1 alpha, murine IL-1 alpha and murine IL-2 beta are transportedfrom blood to brain in the mouse by a shared saturable mechanism. J. Pharmacol.Exp. Ther. 259, 988ā996.
Plata-Salaman, C. and Turrin, N. (1999) Cytokine interactions and cytokine balancein the brain: relevance to neurology and psychiatry. Mol. Psychiatry 4, 303ā306.
Rothwell, N. J. (1999) Cytokinesākillers in the brain. J. Physiol. 514, 3ā17.
Minami, M., Kuraishi, Y., Yamaguchi, T., Nakai, S., Hirai, Y., and Satoh, M. (1991) Immobilization stress induces interleukin-1Ī² mRNA in rat hypothalamus. Neurosci. Lett. 123, 254ā256.
Nguyen, K. T., Deak, T., Owens, S. M., Kohno, T., Fleshner, M., Watkins, L. R.,and Maier, S. F. (1998) Exposure to acute stress induces brain interleukin-113 protein in the rat. J. Neurosci. 18, 2239ā2246.
Nguyen K. Y., Deak, T., Hunsaker, B., Fleshner, M., Watkins, L. R., and Maier, S. (1999) Effects of stress on interleukin-113 and interleukin-6 protein in thebrain and periphery. PNIRS Meeting P1. 37, Abst #98.
Shintani, F., Nakaki, T., Kanba, S., Sato, K., Kato, R., and Asai, M. (1995) Roleof interleukin-1 in stress responses. Mol. Neurobiol. 10, 47ā71.
Plata-SalamĆ”n, C. R., Ilyin, S. E., Gayle, D., Flynn, M. C., Turrin, N. P., Bedard, T.,et al. (2000) Neither acute nor chronic exposure to a naturalistic (predator) stressorinfluences the IL-1Ī² system, TNF-Ī±, TGF-Ī²1, and neuropeptide mRNAs, CRH orbombesin content in specific brain regions. Brain Res. Bull. 51, 187ā193.
Ericsson, A., Kovacs, K. J., and Sawchenko, P. E. (1994) A functionalanatomical analysis of central pathways subserving the effects of interleukin-1on stress-related neuroendocrine neurons. J. Neurosci. 14, 89ā91.
Rivest S. and Rivier C. (1994) Stress and interleukin-1 beta-induced activationof c-Fos, Ngfi-B and CRF gene expression in the hypothalamic PVNācomparison between Sprague-Dawley, Fisher-344 and Lewis rats. J. Neuroendocrinol. 6, 101ā117.
Turnbull, A. V. and Rivier, C. (1996) Cytokine effects on neuroendocrine axes:influence of nitric oxide and carbon monoxide, in Cytokines in the NervousSystem (Rothwell, N. J., ed.), R. G. Landes, London, pp. 93ā116.
Dunn, A. J. (1992) Endotoxin-induced activation of cerebral catecholamine andserotonin metabolism: comparison with interleukin-1. J. Pharmacol. Exp. Ther. 261, 964ā969.
Lacosta, S., Merali, Z., and Anisman, H. (1998) Influence of interleukin-1 onexploratory behavior, plasma ACTH and corticosterone, and central biogenicamines in mice. Psychopharmacology 137, 351ā361.
Lacosta, S., Merali, Z., and Anisman, H. (1999) Behavioral and neurochemicalconsequences of lipopolysaccharide in mice: anxiogenic-like effects. Brain Res. 818, 291ā303.
Anisman, H. and Merali, Z. (1999) Anhedonic and anxiogenic effects of cytokineexposure. Adv. Exp. Med. Biol. 461, 199ā233.
Gemma, C., Ghezzi, P., and De Simoni, M. G. (1991) Activation of the hypothalamic serotonergic system by central interleukin-1. Eur. J. Pharmacol. 209,139ā140.
Mohankumar, P. S. and Quadri, S. K. (1993) Systemic administration ofinterleukin-1 stimulates norepinephrine release in the paraventricular nucleus.Life Sci. 52, 1961ā1967.
Mohankumar, P. S., Thyagarajan, S., and Quadri, S. K. (1991) Interleukin-1st imulates the release of dopamine and dihydroxyphenylacetic acid from hypothalamus in vivo. Life Sci. 48, 925ā930.
Smagin, G. N., Swiergiel, A. H., and Dunn, A. J. (1996) Peripheral administration ofinterleukin-1 increases extracellular concentrations of norepinephrine in rathypothalamus: comparison with plasma corticosterone. Psychoneuroendocrinology 21, 83ā93.
Linthorst, A. C. E., Flachskamm, C., Muller-Preuss, P., Holsboer, F., and Reul, J. M. H. M. (1995) Effect of bacterial endotoxin and interleukin-113 onhippocampal serotonergic neurotransmission, behavioral activity, and freecorticosterone levels: an in vivo microdialysis study. J. Neurosci. 15, 2920ā2934.
Merali, Z., Lacosta, S., and Anisman, H. (1997) Effects of interleukin-1Ī² andmild stress on alterations of central monoamines: a regional microdialysis study.Brain Res. 761, 225ā235.
Song, C., Merali, Z., and Anisman, H. (1998) Variations of nucleus accumbensdopamine and serotonin following systemic interleukin-1, interleukin-2 orinterleukin-6 treatment. Neuroscience 88, 823ā836.
Hayley, S., Brebner, K., Merali, Z., and Anisman, H. (1999) Sensitization to theeffects of tumor necrosis factor-Ī±: neuroendocrine, central monoamine, andbehavioral variations. J. Neurosci. 19, 5654ā5665.
Deutch, A. Y. and Roth, R. H. (1990) The determinants of stress-induced activation of the prefrontal cortical dopamine system. Prog. Brain Res. 85, 367ā403.
Borowski, T., Kokkinidis, L., Merali, Z., and Anisman, H. (1998) Lipopolysaccharide, central in vivo amine alterations, and anhedonia. Neuroreport 9, 3797ā3802.
Tilders, F. J. H. and Schmidt, E. D. (1998) Interleukin-1-induced plasticity ofhypothalamic CRH neurons and long-term stress hyperresponsiveness. Ann. NYAcad. Sci. 840, 65ā73.
Tilders, F. J. H., Schmidt, E. D., and De Goeij, D. C. E. (1993) Phenotypicplasticity of CRF neurons during stress. Ann. NY Acad. Sci. 697, 39ā52.
Schmidt, E. D., Janszen, A. W. J. W., Wouterlood, F. G., and Tilders, F. J. H.(1995) Interleukin-1 induced long-lasting changes in hypothalamiccorticotropin-releasing hormone (CRH) neurons and hyperresponsiveness of thehypothalamic-pituitary-adrenal axis. J. Neurosci. 15, 7417ā7426.
Herbert T. B. and Cohen, S. (1993) Depression and immunity: a meta-analyticreview. Psychol. Bull. 113, 472ā486.
Herbert, T. B. and Cohen, S. (1993) Stress and immunity in humans: a metaanalytic review. Psychosom. Med. 55, 364ā379.
Irwin, M. (1999) Immune correlates of depression. Adv. Exp. Med. Biol. 461, 1ā24.
Weisse, C. S. (1992) Depression and immunocompetence: a review of the literature. Psychol. Bull. 113, 475ā586.
Irwin, M. R., Smith, T. L., and Gillin, J. C. (1992) Electroencephalographic sleepand natural killer cell activity in depressed patients and control subjects.Psychosom. Med. 54, 10ā21.
Stein, M., Keller, S. E., and Schleifer, S. J. (1982) The role of brain and theneuroendocrine system in immune regulation-potential links to neoplasticdiseases, in Biological Mediators of Behavior and Disease: Neoplasia (Levy, S. M.,ed.), Elsevier, NY, pp. 147ā174.
Sluzewska, A. (1999) Indicators of immune activation in depressed patients.Adv. Exp. Med. Biol. 461, 59ā74.
Berk, M., Wadee, A. A., Kuschke, R. H., and O’Neill-Kerr, A. (1997) Acutephase proteins in major depression. J. Psychosom. Res. 43, 529ā534.
Frommberger, U. H., Bauer, J., Haselbauer, P., Fraulin, A., Riemann, D., and Berger, M. (1997) Interleukin-6 (IL-6) plasma levels in depression and schizophrenia: comparison between the acute state and after remission. Eur. Arch.Psychiatry. Clin. Neurosci. 247, 228ā233.
Maes, M., Bosmans, E., Meltzer, H. Y., Scharpe, S., and Suy, E. (1993)Interleukin-1Ī²: a putative mediator of HPA axis hyperactivity in major depression? Am. J. Psychiatry 150, 1189ā1193.
Maes, M., Bosmans, E., Suy, E., Vandervorst, C., de Jonckheere, C., Minner, B.,et al. (1991) Depression-related disturbances in mitogen-induced lymphocyteresponses and interleukin-1Ī² and soluble interleukin-2 receptor production. ActaPsychiatr. Scand. 84, 379ā386.
Maes, M., Lambrechts, J., Bosmans, E., Jacobs, J., Suy, E., Vandervorst, C.,et al. (1992) Evidence for a systemic immune activation during depression:results of leukocyte enumeration by flow cytometry in conjunction with monoclonal antibody staining. Psychol. Med. 22, 45ā53.
Maes, M., Meltzer, H. Y., Bosmans, E., Bergmans, R., Vandoolaeghe, E., Ranjan, R., et al. (1995) Increased plasma concentrations of interleukin-6,soluble interleukin-6, soluble interleukin-2 and transferrin receptor in majordepression. J. Affect. Disord. 34, 301ā309.
Mullar, N. and Ackenheil, M. (1998) Psychoneuroimmunology and the cytokineaction in the CNS: implications for psychiatric disorders. Prog. Neuropsychopharm. Biol. Psychiatry 22, 1ā33.
Nassberger, L. and Traskman-Bendz, L. (1993) Increased soluble interleukin-2 receptor concentrations in suicide attempters. Acta Psychiatr. Scand. 88, 48ā52.
Smith, R. S. (1991) The macrophage theory of depression. Med. Hypoth. 35, 298ā306.
Song, C., Dinan, T., and Leonard, B. E. (1994) Changes in immunoglobulin,complement and acute phase protein levels in depressed patients and normalcontrols. J. Affect. Disord. 30, 283ā288.
Maes, M., Bosmans, E., De Jongh, R., Kenis, G., Vandoolaeghe, E., and Neels, H.(1997) Increased serum IL-6 and IL-1 receptor antagonist concentrations inmajor depression and treatment resistant depression. Cytokine 9, 853ā858.
Sluzewska, A., Rybakowski, J. K., Laciak, M., Mackiewicz, A., Sobieska, M.,and Wiktorowicz, K. (1995) Interleukin-6 serum levels in depressed patientsbefore and after treatment with fluoxetine. Ann. NYAcad. Sci. 762, 474ā476.
Anisman, H., Ravindran, A. V., Griffiths, J.. and Merali, Z. (1999) Endocrineand cytokine correlates of major depression and dysthymia with typical or atypical features. Mol. Psychiatry 4, 182ā188.
Anisman, H., Ravindran, A. V., Griffiths, J., and Merali, H. (1999) Interleukin-1 variations associated with dysthymia prior to and following antidepressantmedication. Biol. Psychiatry 46, 1649ā1655.
Maes, M., Scharpe, S., Meltzer, H. Y., Bosmans, E., Suy, E., Calabrese, J., and Cosyns, P. (1993) Relationships between interleukin-6 activity, acute phaseproteins, and function of the hypothalamic-pituitary-adrenal axis in severedepression. Psychiatry Res. 49, 11ā27.
Seidel, A., Arolt, V., Hunstiger, M., Rink, L., Behnisch. A., and Kirchner, H.(1995) Cytokine production and serum proteins in depression. Scand. J.Immunol. 41, 534ā538.
Griffiths, J., Ravindran, A. V., and Merali, Z., and Anisman, H. (2000) Dysthymia:neurochemical and behavioral perspectives. Mol. Psychiatry 5, 242ā261.
Capuron, L., Ravaud, A., Radat, F., Dantzer, R., and Goodall, G. (1998) Affectsof interleukin-2 and alpha-interferon cytokine immunotherapy on the mood andcognitive performance of cancer patients. Neuroimmunomodulation 5, 9.
Caraceni, A., Martini, C., Belli, F., Mascheroni, L., Rivoltini, L., Arienti, F.,et al. (1992) Neuropsychological and neurophysiological assessment of the cen-tral effects of interleukin-2 administration, Eur. J. Cancer 29A, 1266ā1269.
Denicoff, K. D., Rubinow, D. R., Papa, M. Z., Simpson, L., Seipp, L. A., Lotze, M. T., et al. (1987) The neuropsychiatric effects of treatment withinterleukin-2 and lymphokine-activated killer cells. Ann. Intern. Med. 107,293ā300.
Meyers, C. A. and Valentine, A. D. (1995) Neurological and psychiatric adverseeffects of immunological therapy. CNS Drugs 3, 56ā68.
Anisman, H. and Merali, Z. (1999) Cytokines and stress in relation to anxiety andanhedonia, in Cytokines, Stress and Depression (Dantzer, R., Wollmann, E. E.,and Yirmiya, R., eds.),Plenum, London, pp. 199ā223.
Yirmiya, R. (1996) Endotoxin produces a depressive-like episode in rats. BrainRes. 711, 163ā174.
First, M. B., Gibbon, M., Soitzer, R. L., and Williams, J. B. W. (1996) User’sGuide for the Structured Clinical Interview for DSM-IV Axis I DisordersāResearch Version. Biometrics Research, NY.
Guy, W. (1976) ECDEU Assessment Manual for psychopharmacology. NIMH,Psychopharmacology Research Branch, Bethesda, MD.
Hamilton, M. (1967) Development of a rating scale for primary depressiveillness. Br. J. Soc. Clin. Psychol. 6, 278ā298.
Liebowitz, M. R., Quikin, F. M., Stewart, J. W., McGrath, P. J., Harrison, W.M., Markowitz, J. S., et al. (1988) Antidepressant specificity in atypicaldepression. Arch. Psychiatry 45, 129ā137.
Montgomery, S. A. and Asberg, M. (1979) A new depression scale designed tobe sensitive to change. Br. J. Psychiatry 134, 382ā389.
Millon, T. (1987) Manual for the Millon Clinical Multiaxial Inventory-II, 2nd ed. National Computer Systems, Minneapolis.
Sheehan, D., Lecrubier, Y., Janavs, J., Knapp, E., Weiller, E., Sheehan, M., et al. (1998) Mini-international Neuropsychiatric Interview. Clinician-Rated.Version 2. 1. University of South Florida Institute for Research in Psychiatry, Tampa, Florida, and INSERM-HĆ“pital de la SalpĆŖtriĆØre, Paris, France.
Beck, A. T., Ward, C. H., Mendelson, M., Mock, J., and Erbaugh, J. (1961) Aninventory for measuring depression. Arch. Gen. Psychiatry 4, 561ā569.
Paykel, E. S., Prusoff B. A., and Uhlenhuth, E. H. (1971) Scaling of life events.Arch. Gen. Psychiatry 25, 340ā347.
Kanner, A. D., Coyne, J. C., Schaefer, C., and Lazarus, R. S. (1981) Comparisonof two modes of stress measurement: daily hassles and uplifts versus major lifeevents. J. Behav. Med. 4, 1ā39.
Beckham, E. E. and Adams, R. L. (1984) Coping behavior in depression: reporton a new scale. Behav. Res. Ther. 22, 71ā75.
Ravicki, D. A., Turner, R., Brown, R., and Martindale, J. J. (1992) BatelleQuality of Life Scale. Qual. Life. Res. 1, 257ā266.
Brown, G. W. and Harris, T. O. (1978) Social Origins of Depression: A Study ofPsychiatric Disorder in Women. Free Press, NY.
Seegal, R. F., Brosch, K. O., and Bush, B. (1986) High-performance liquidchromatography of biogenic amines and metabolites in brain, cerebrospinal fluid,urine and plasma. J. Chromatogr. 377, 141ā144.
Baroja, M. L. and Cueppens, J. L. (1987) More exact quantification ofinterleukin-2 production by addition of anti-Tac monoclonal antibody to culturesof stimulated lymphocytes. J. Immunol. Methods 98, 267ā270.
De Groote, D., Gevaert, Y., Lopez, M., Gathy, R., Fauchet, F., Dehart, I., et al.(1993) Novel method for the measurement of cytokine production by a one-stage procedure. J. Immunol. Methods 163, 259ā267.
Mason, B. J., Kocsis, J. H., Leon, A. C., Thompson, S., Frances, A. J., Morgan, R. O., and Parides, M. K. (1993) Measurement of severity and treatment responsein dysthymia. Psychiatr. Ann. 23, 625ā631.
Ravindran, A., Griffiths, J., Waddell, C., and Anisman, H. (1995) Stressful lifeevents and coping styles in dysthymia and major depressive disorder: variationsassociated with alleviation of symptoms following pharmacotherapy. Prog.Neuropsychopharmacol. Biol. Psychiatry. 19, 637ā653.
Kiecolt-Glazer, J. K. and Glazer, R. (1991) Stress and immune function inhumans, in Psychoneuroimmunology (Ader, R., Felten, D. L., and Cohen, N.,eds.), Academic, San Diego, CA, pp. 849ā867.
Irwin, M. R., Caldwell, C., Smith, T. L., Brown, S., Schuckit, M. A., and Gillin, J. C. (1990) Major depressive disorder, alcoholism, and reduced natural killercytotoxicity: role of severity of depressive symptoms and alcohol consumption.Arch. Gen. Psychiatry 47, 713ā719.
Irwin, M. R., Patterson, T. L., Smith, T. L., Caldwell, C., Brown, S., Gillin, J. C.,et al. (1990) Reduction of immune function in life stress and depression. Biol.Psychiatry 27, 22ā30.
Ravindran, A. V., Griffiths, J., Merali, Z., and Anisman, H. (1998) Circulatinglymphocyte subsets in major depression and dysthymia with typical or atypicalfeatures. Psychosom. Med. 60, 283ā289.
Quitkin, F. M., Harrison, W. M., Stewart, J. W., McGrath, P. J., Tricamo, E., Ocepek-Welikson, K., et al. (1991) Response to phenelzine and imipramine inplacebo responders with atypical depression. Arch. Gen. Psychiatry 48, 319ā323.
Nemeroff, C. B. (1996) The corticotropin-releasing factor (CRF) hypothsesis ofdepression: new findings and new directions. Mol. Psychiatry 1, 336ā342.
McGinn, L. K., Asnis, G. M., and Rubinson, E. (1996) Biological and clinicalvalidation of atypical depression. Psychiat. Res. 60, 191ā198.
McGrath, P. J., Stewart, J. W., Harrison, W. M., Ocepek-Wilekson, K., Rabkin, J. G., Nunes, E. N., et al. (1992) Predictive value of symptoms of atypical depression fordifferential drug treatment outcome. J. Clin. Psychopharmacol. 12, 197ā202.
Moldofsky, H. (1995) Sleep and the immune system. Int. J. Immunopharmacol. 17, 649ā654.
Cover, H. and Irwin, M. (1994) Immunity and depression: insomnia, retardationand reduction of natural killer cell activity. J. Behav. Med. 17, 217ā223.
Petrovsky, N. and Harrison, L. C. (1997) Diurnal rhythmicity of human cytokineproduction. J. Immunol. 158, 5163ā5168.
Demitrack, M. A., Dale, J. K., Straus, S. E., Laue, L., Listwak, S. J., Kruesi, M.J. P., et al. (1991) Evidence for impaired activation of the hypothalamic-pituitary-adrenal axis in patients with chronic fatigue syndrome. J. Clin. Endocrinol.Metab. 148, 337ā344.
Gold, P. W., Licinio, J., Wong, M. L., and Chrousos, G. P. (1995) Corticotropin releasing hormone in pathophysiology of melancholic and atypical depression and in themechanism of action of antidepressant drugs. Ann. NYAcad. Sci. 771, 716ā729.
Joseph-Vanderpool, J. R., Rosenthal, N. E., Chrousos, G. P., Wehr, T. A., Skwerer, R., Kasper, S., and Gold, P. W. (1991) Abnormal pituitary-adrenalresponses to corticotropin-releasing hormone in patients with seasonal affectivedisorder: clinical and pathophysiological implications. J. Clin. Endocrinol.Metab. 72, 1382ā1387.
Levitan, R. D., Kaplan, A. S., Brown, G. M., Joffe, R. T., Levitt, A. J., Vaccarino, F. J., et al. (1997) Low plasma cortisol in bulimia nervosa patients with reversedneurovegetative symptoms of depression. Biol. Psychiatry 41, 366ā368.
Zaharia, M. D., Ravindran, A. V., Griffiths, J., Merali, Z., and Anisman, H.(2000) Lymphocyte proliferation among major depressive and dysthymicpatients with typical or atypical features. J. Affect. Disord. 58, 1ā10.
Griffiths, A. V. Ravindran, Z., Merali, Z., and Anisman, H. (1996) Immune andbehavioral correlates of typical and atypical depression. Soc. Neurosci. (Abst)22, 1350.
Schulkin, J., Gold, P. W., and McEwen, B. S. (1998) Induction of corticotropin-releasing hormone gene expression by glucocorticoids: implication for understanding thestates of fear and anxiety and allostatic load. Psychoneuroendocrinology 23, 219ā243.
Post, R. M. (1992) Transduction of psychosocial stress into the neurobiology ofrecurrent affective disorder. Am. J. Psychiatry 149, 999ā1010.
Post, R. M. and Weiss, S. R. B. (1995) The neurobiology of treatment-resistantmood disorders, in Psychopharmacology: The Fourth Generation of Progress (Bloom, F. E. and Kupfer, D. J., eds.), Raven, NY, pp. 1155ā1170.
Ravindran, A. V., Anisman, H., Merali, Z. Charbonneau, Y., Telner, J., Bialik, R. J., et al. (1999) Treatment of primary dysthymia with cognitive therapy andpharmacotherapy: clinical symptoms and functional Impairments. Am. J.Psychiatry 156, 1608ā1617.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
Ā© 2001 Humana Press Inc.
About this protocol
Cite this protocol
Anisman, H., Hayley, S., Ravindran, A.V., Merali, Z., Griffiths, J. (2001). Cytokines, Stress, and Depressive Illness. In: OāNeill, L.A.J., Bowie, A. (eds) Interleukin Protocols. Methods in Molecular Medicineā¢, vol 60. Springer, Totowa, NJ. https://doi.org/10.1385/1-59259-146-9:217
Download citation
DOI: https://doi.org/10.1385/1-59259-146-9:217
Publisher Name: Springer, Totowa, NJ
Print ISBN: 978-0-89603-738-0
Online ISBN: 978-1-59259-146-6
eBook Packages: Springer Protocols